Convergent validity of VITACORA-19 overall score with EQ-5D VAS, PsA activity assessments, axial night pain intensity, and PsA global activity estimation by clinician and patients.
| Clinical Assessments | Pearson’s r | VITACORA–19 Global Score |
|---|---|---|
| EQ-5D (VAS) | ||
| VAS | r | –0.493** |
| n | 197 | |
| PsA activity assessments | ||
| ESR | r | –0.287** |
| n | 180 | |
| CRP | r | –0.042 |
| n | 183 | |
| BSA | r | –0.664 |
| n | 180 | |
| BASFI | r | –0.197 |
| n | 191 | |
| BASDAI | r | –0.055 |
| n | 39 | |
| DAS-28 | r | –0.423** |
| n | 118 | |
| Axial night pain intensity | r | 0.029 |
| n | 195 | |
| PsA global activity | ||
| According to clinician | r | 0.566** |
| n | 197 | |
| According to patients | r | 0.234* |
| n | 197 |
↵* The correlations were statistically significant at p < 0.01.
↵** The correlations were statistically significant at p < 0.001. VITACORA-19: PsA quality of life questionnaire; EQ-5D: EuroQol questionnaire; PsA: psoriatic arthritis; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BSA: body surface area; BASFI: Bath Ankylosing Spondylitis Function Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; DAS28: 28-joint Disease Activity Score.